Abstract

The Molecular Diagnosis and Risk Stratification of Sepsis (MARS) consortium aims to generate tools that provide rapid and accurate information about an individual patient suffering from sepsis, including which microorganism is responsible for the infection and the severity and stage of the immune response. These tools should be easy to use, be at or close to the patient's bedside, and provide rapid information to the physician about how to treat each individual patient in the best way.

Mission

The program is organized into the following four Work Packages (WPs):

Consortium History
2010: Consortium started  
2013: Data collection completed  
2015: Consortium scheduled to complete

Financing

In response to the first call for project proposals in 2007, the Center for Translational Molecular Medicine (CTMM) announced on April 1, 2008, that nine first-call projects would receive research funding amounting to a total of €150 million. On March 10, 2009, it announced that eight new project proposals, submitted in the fall of 2008 in response to the second call for proposals, would receive funding amounting to a total of almost €100 million.

All Dutch university medical centers, plus several universities, a broad spectrum of small and medium-sized enterprises, major industry leaders including Philips and DSM Biomedical Materials, and the Dutch government are involved.

Funding is provided by the Dutch government, industry, and academia. Research is focused firmly on the translational aspects of molecular medicine so that results can be applied as quickly as possible to actual patient care.

MARS is one of the projects from the second call, with a project budget of €14 million, of which 50 percent is contributed by the Dutch government.

Other website  
https://www.myctmm.nl/pro1/general/start.asp?i=5&j=2&k=0&p=0&itemid=75&folder=Infection%20and%20Immunity&title=Mars%20(Infectious%20diseases)

Points of Contact

Principal investigator: Tom van der Poll (Academic Medical Center, Amsterdam)  
CTMM program manager: Henny Bruinewoud
Sponsors & Partners

Academisch Medisch Centrum (AMC)  
Amsterdam  
BioCartis  
Check-Points Health BV  
Immunetrics Inc.  
Immunexpress  
Microbiome Ltd.  
Philips Electronics Nederland BV  
Universitair Medisch Centrum St Radboud, Nijmegen  
Universitair Medisch Centrum Utrecht (UMCU)

Updated: **04/08/2016**